STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib

Bibliographic Details
Main Authors:	Misako Nagasaka, MD, Nagaratna Sarvadevabatla, MD, Shawn Iwata, BSN, Yubin Ge, PhD, Ammar Sukari, MD, Christian Klosowski, MS, Ronald Yanagihara, MD
Format:	Article
Language:	English
Published:	Elsevier 2021-02-01
Series:	JTO Clinical and Research Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364320301764

Similar Items

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
by: Hao Zeng, et al.
Published: (2021-08-01)

STRN-ALK Fusion in Lung Adenocarcinoma with Excellent Response Upon Alectinib Treatment: A Case Report and Literature Review
by: Su C, et al.
Published: (2020-12-01)

Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
by: Kunyan Sun, et al.
Published: (2021-06-01)

Identification of a recurrent STRN/ALK fusion in thyroid carcinomas.
by: Gaëlle Pérot, et al.
Published: (2014-01-01)

A Rare STRN-ALK Fusion in Lung Adenocarcinoma Identified Using Next-Generation Sequencing–Based Circulating Tumor DNA Profiling Exhibits Excellent Response to Crizotinib
by: Yan Yang, MD, PhD, et al.
Published: (2017-07-01)

Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC
by: Catherine Daniel, MD, PhD, et al.
Published: (2020-11-01)

Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020
by: Sai-Hong Ignatius Ou, MD, PhD, et al.
Published: (2020-03-01)

A Novel LINC00478/LINC01549 Intergenic Region-ALK Fusion Responded Well to Alectinib in a Patient With Lung Adenocarcinoma
by: Wei Peng, MS, et al.
Published: (2021-01-01)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01)

ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
by: Ray Sagawa, et al.
Published: (2018-01-01)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
by: Maiken Parm Ulhoi, et al.
Published: (2021-09-01)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
by: Satoh H, et al.
Published: (2021-04-01)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
by: Muhammad Wasi Alam, et al.
Published: (2019-07-01)

Clinical case of prolonged use of alectinib in the treatment of ALK-positive NSCLC
by: S. G. Bagrova, et al.
Published: (2019-12-01)

KRAS mutation as a mechanism of resistance to Alectinib in ALK rearranged NSCLC
by: Ullas Batra, et al.
Published: (2021-03-01)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
by: Alfredo Addeo, et al.
Published: (2018-07-01)

Focus on Alectinib and Competitor Compounds for Second Line Therapy in ALK Rearranged NSCLC
by: Samuel J Klempner, et al.
Published: (2016-11-01)

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
by: Peng L, et al.
Published: (2021-05-01)

STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells
by: Astrid Murumägi, et al.
Published: (2021-04-01)

Colorectal Cancer with EML4-ALK Fusion Gene Response to Alectinib: A Case Report and Review of the Literature
by: Sheng-Yen Hsiao, et al.
Published: (2021-03-01)

ALK Rearrangement Adenocarcinoma with Histological Transformation to Squamous Cell Carcinoma Resistant to Alectinib and Ceritinib
by: Kaiho T, et al.
Published: (2020-02-01)

The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis
by: Fan JS, et al.
Published: (2018-03-01)

Dramatic response to alectinib in a patient with ALK‐rearranged squamous cell lung cancer
by: Jun Shiihara, et al.
Published: (2021-09-01)

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
by: Zhu VW, et al.
Published: (2018-11-01)

Alectinib-associated drug reaction with eosinophilia and systemic symptoms syndrome
by: Sahira Farooq, BS, et al.
Published: (2020-12-01)

Hemolytic anemia caused by alectinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor: A case report
by: Aerts, R., et al.
Published: (2022)

Complete response to alectinib following crizotinib in an ALK-positive inflammatory myofibroblastic tumor with CNS involvement
by: Camila B. Xavier, et al.
Published: (2021-12-01)

Switching to an alternative ALK-inhibitor after alectinib-induced pneumonitis resulted in resolution of this adverse event
by: Evan Bryson, et al.
Published: (2020-12-01)

Successful Alectinib Treatment for Carcinoma of Unknown Primary with <i>EML4-ALK</i> Fusion Gene: A Case Report
by: Keiji Sugiyama, et al.
Published: (2021-05-01)

ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
by: Nobuaki Mamesaya, et al.
Published: (2017-07-01)

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
by: Karachaliou N, et al.
Published: (2019-06-01)

Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance
by: Zilan Song, et al.
Published: (2015-01-01)

Treatment of ALK Positive Non-small Cell Lung Cancer with Alectinib:  A Case Report and Literature Review
by: Haixiang YANG, et al.
Published: (2021-09-01)

Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model
by: Tsuji, Takahiro
Published: (2019)

Dramatic response to alectinib in an ALK‐positive LCNEC patient with a poor performance status: A case report
by: Kazuki Masuda, et al.
Published: (2021-09-01)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
by: Xing Huang
Published: (2018-02-01)

Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction
by: Shimada M, et al.
Published: (2017-06-01)

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells
by: Xuyuan Dong, et al.
Published: (2016-03-01)

Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
by: Yu H, et al.
Published: (2019-08-01)

Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer
by: Okuma Y, et al.
Published: (2015-06-01)